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Background: Hydralazine (Hyd) and isosorbide dinitrate (ISDN) decrease mortality in African Americans (AA) with systolic heart failure (sHF). 
However, whether both agents or one alone decrease mortality in AA has yet to be studied. We examined if the combination of Hyd-ISDN is superior 
to either Hyd or ISDN alone in AA.
Methods: Retrospectively, we identified all AA patients at Montefiore Medical Center who, from 2000-10, were diagnosed with sHF with an 
LVEF≤35% via echo, and were on ACE inhibitors or ARBs and ß-blockers. Patients were grouped based on those started on both Hyd-ISDN, only Hyd, 
only ISDN, or neither Hyd or ISDN. The major endpoint was 5 year all-cause mortality.
Results: After multivariate analysis, patients receiving both Hyd-ISDN (Cohort I), only Hyd (Cohort II), or only ISDN (Cohort III) exhibited a 
significantly lower mortality rate through 5 years (I=37%, II=39%, III=43%) compared with those not receiving either Hyd or ISDN (Cohort IV, 56%; 
overall p<0.001). However, a significant mortality difference was not observed between those started on both Hyd-ISDN, only Hyd, or only ISDN (I vs. 
II p=0.8, I vs. III p=0.08, II vs. III p=0.1)
 
Conclusions: AA who were started on Hyd-ISDN, only Hyd or only ISDN had a lower mortality rate compared to those not started on either Hyd or 
ISDN. However, the combination of both Hyd and ISDN did not afford a mortality benefit compared to either agent alone. Thus, the mortality benefit 
afforded to AA with Hyd-ISDN does not appear to require both agents.
